COMPASS Pathways plc (CMPS)

Market Cap	348.45M
Revenue (ttm)	n/a
Net Income (ttm)	-137.80M
Shares Out	92.67M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	585,097
Open	3.940
Previous Close	3.740
Day's Range	3.630 - 3.940
52-Week Range	2.490 - 9.630
Beta	2.28
Analysts	Strong Buy
Price Target	20.20 (+437.23%)
Earnings Date	May 8, 2025

About CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 166
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS
• Website: https://compasspathways.com

Analyst Forecast

According to 6 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is $20.2, which is an increase of 437.23% from the latest price.

Price Target

$20.2

(437.23% upside)

Analyst Consensus: Strong Buy